DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



The Safe Effective Light Dose of Photodynamic Therapy for Chronic Central Serous Chorioretinopathy

Information source: Yeungnam University College of Medicine
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Central Serous Chorioretinopathy

Intervention: Photodynamic therapy (Procedure)

Phase: N/A

Status: Recruiting

Sponsored by: Yeungnam University College of Medicine

Overall contact:
Min Sagong, Phone: 82-53-620-4191, Email: msagong@ynu.ac.kr

Summary

To find the safe effective lowest light dose for photodynamic therapy (PDT). in the treatment of central serous chorioretinopathy.

Clinical Details

Official title: The Safe Effective Light Dose of Photodynamic Therapy for Chronic Central Serous Chorioretinopathy

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Changes of best corrected visual acuity

Secondary outcome: Change of central retinal thickness, success rate, recurrence rate, and complications

Eligibility

Minimum age: 20 Years. Maximum age: 70 Years. Gender(s): Both.

Criteria:

Inclusion Criteria: 1. Idiopathic detachment of the neurosensory retina with a focal leak at the level of the RPE with FA 2. Presence of SRF and/or serous pigment epithelial detachment on optical coherence tomography (OCT) 3. Presence of abnormal dilated choroidal vasculature in ICGA 4. Patients with symptomatic CSC of at least 3 months duration Exclusion Criteria: 1. Patients who received any previous treatment, including PDT or focal thermal laser photocoagulation for CSC, or who had evidence of CNV, PCV, or other maculopathy on clinical examination, FA, or ICGA 2. Patients receiving exogenous corticosteroid treatment 3. Patients with systemic diseases such as Cushing's disease or renal diseases 4. Pregnant patients

Locations and Contacts

Min Sagong, Phone: 82-53-620-4191, Email: msagong@ynu.ac.kr

Yeungnam University College of Medicine, Daegu, Korea, Republic of; Recruiting
Min Sagong, Phone: 82-53-620-4191, Email: msagong@ynu.ac.kr
Min Sagong, Principal Investigator
Additional Information

Starting date: June 2012
Last updated: February 13, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017